Skip to main content
x

SERVIER IN CARDIOLOGY

ESC 2020 Congress

DISCOVER MORE

SERVIER GROUP

Around the world, the Servier Group’s 22,000 employees are committed to therapeutic progress in cardiology to serve patient needs.

Cardiovascular diseases are the leading cause of mortality in the world and are responsible for 31% of deaths every year. Committed for more than 60 years to the treatment of these pathologies, Servier has acquired recognized expertise and leadership in Cardiology.

More than 17 million patients worldwide are being treated every day with a Servier medicine for a condition affecting the heart or blood vessels.

SERVIER IN CARDIOLOGY:

12

drug candidates

6TH

largest player worldwide and 2nd in Europe

16

medicines available to health care professionals and patients

Servier continues to innovate in cardiology: by developing new products and services for and with patients.

Servier has been a major sponsor of the ESC for many years and will again be one of the leading pharmaceutical companies present at the 2020 congress, bringing together a variety of activities: portfolio offer, medical affairs, disease awareness campaigns as well as new technologies with a space dedicated to WeHealth. Many scientific symposiums will be organized by the Servier Group to share the latest medical data on hypertension, angina and heart failure.

The aim of Servier’s teams at virtual ESC congress: present the therapeutic solutions of the Group to healthcare professionals and provide them with a wide range of information on the products and services, especially adapted in the Covid-19 context.

AREAS

Register now on ESC website to discover Servier’s disease awareness activities at ESC virtual booth for the following areas

Hypertension

If you want to know more about Servier disease awareness project Because I Say So

click here

Angina

If you want to know more about our awareness campaign Angina Awareness Initiative

click here

Our partnership

If you want to know more about Disease State Education and the role of contractility in heart failure

click here

Dyslipidemia

If you want to learn more about dyslipidemia and our awareness campaign

click here

Heart failure

If you want to know more about the disease management program OPTIMIZE Heart Failure care

click here

E-health

If want to learn more about our solutions in digital health

click here

IT'S NEVER TOO LATE!
WATCH NOW ON DEMAND OUR Q&A SESSIONS

Discover our Q&A live sessions at ESC Congress 2020 - The digital Experience.

HEARTH FAILURE

Improving Heart Failure outcomes: are we entering a new era of Heart Failure treatment?

Chairpersons: Prof. Andrew Coats (UK) and Prof. John McMurray (UK)

ANGINA

Managing angina and ischemic disease: what have we learned in 2020?

Chairperson: Prof. Giuseppe Rosano (UK)

DYSLIPIDEMIA

Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy

 

HYPERTENSION

Triple single-pill combination in the management of hypertension: earlier and broader use?

Chairperson: C. Tsioufis (Greece)

HYPERTENSION

Tackling cardiovascular diseases with a new generation of polypills

Chairperson: C. Vlachopoulos (Greece)

WeHealth

Digital Health: the new normal

Chairpersons: M. Komajda (France) and M. Cowie (UK)

WEBINARS COVID-19

Discover how Covid-19 has impacted on Doctors’ pratices and Patients’ disease management.


Want to know more?

REGISTER